...
首页> 外文期刊>International braz j urol >The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux
【24h】

The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux

机译:两种不同膨化剂(葡聚糖透明质酸共聚物和聚丙烯酸酯 - 多元醇共聚物)的结果在治疗原发性VESIC-ineteral回流中

获取原文
           

摘要

Purpose Subureteral injection of bulking agents in the endoscopic treatment of vesicoureteral reflux is widely accepted therapy with high success rates. Although the grade of vesicoureteric reflux and experience of surgeon is the mainstay of this success, the characteristics of augmenting substances may have an effect particularly in the long term. In this retrospective study, we aimed to evaluate the clinical outcomes of the endoscopic treatment of vesicoureteric reflux (VUR) with two different bulking agents: Dextranomer/hyaluronic acid copolymer (Dx/HA) and Polyacrylate polyalcohol copolymer (PPC). Materials and Methods A total 80 patients (49 girls and 31 boys) aged 1-12 years (mean age 5.3 years) underwent endoscopic subureteral injection for correction of VUR last six years. The patients were assigned to two groups: subureteral injections of Dx/HA (45 patients and 57 ureters) and PPC (35 patients and 45 ureters). VUR was grade II in 27 ureters, grade III in 35, grade IV in 22 and grade V in 18 ureters. Results VUR was resolved in 38 (66.6%) of 57 ureters and this equates to VUR correction in 33 (73.3%) of the 45 patients in Dx/HA group. In PPC group, overall success rate was 88.8% (of 40 in 45 ureters). Thus, Thus, this equates to VUR correction in 31 (88.5%) of the 35 patients. Conclusions Our short term data show that two different bulking agent injections provide a high level of reflux resolution and this study revealed that success rate of PPC was significantly higher than Dx/HA with less material.
机译:目的次镜次镜下治疗中的膨胀剂杂散回流是广泛接受的,具有高成功率的疗法。虽然vesicouretic反流的等级和外科医生的经验是这一成功的主干,但增强物质的特点可能在长期内具有效果。在这项回顾性研究中,我们旨在评估用两种不同的填充剂:葡糖体/透明质酸共聚物(DX / HA)和聚丙烯酸酯多元醇共聚物(PPC)对杂散管状物回流(VUR)的临床结果。材料和方法共有80例患者(49名女孩和31名男孩)1-12岁(平均5.3岁)接受了内窥镜次生吸入,用于校正VUR的校正。将患者分配到两组:DX / HA(45名患者和57例患者)和PPC(35名患者和45例患者)的次生目注射。 VUR是27次尿素,III级,35级,IV级,22级,v等级,18岁尿素。结果VUR在38(66.6%)的57次输尿管中得到了解决,这相当于DX / HA集团45名患者的33名(73.3%)的VUR校正。在PPC集团中,总体成功率为88.8%(40例45磅)。因此,这相当于35例患者的31例(88.5%)的VUR校正。结论我们的短期数据显示,两种不同的填充剂注射提供高水平的回流分辨率,本研究显示PPC的成功率明显高于DX / HA,具有较少的材料。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号